ABSTRACT
Purpose
The aim is to increase the understanding of lacrimal gland pleomorphic adenoma’s recurrence rate and the factors that influence it.
Methods
A systematic search of PubMed, SCOPUS, Cochrane Library, and CINAHL was conducted following PRISMA guidelines. The data in the included studies were extracted and analyzed.
Results
Twenty-two studies were included representing 963 patients from 12 different countries. The pooled analysis of the recurrence rate was 8.83% (95% CI: 5.08–13.50). In the event of recurrence, there was a 75.17% (95% CI: 65.98–82.94) chance of benign recurrence and a 28.35% (95% CI: 19.66–38.41) chance of malignant recurrences, with malignant recurrence occurring almost exclusively after a benign recurrence. The results showed that 47.09% (95% CI: 24.60 to 70.22) of recurrent tumors had a ruptured pseudocapsule and 6.35% (95% CI: 0.82 to 16.54) had an intact pseudocapsule with a significant difference between the two. Of the recurrent tumors, 51.50% (95% CI: 9.28 to 92.39) were biopsied compared to 8.83% (95% CI: 3.40 to 16.49) of the total; the difference between these two proportions was also found to be significant.
Conclusion
There was a statistically significant difference in the rates of recurrence between tumors that were either biopsied or had a ruptured pseudocapsule compared to those that did not. This evidence adds additional support for excisional biopsy being the procedure of choice for LGPA and reinforces the importance of keeping the pseudocapsule intact during surgical resection.
Disclosure statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Disclaimer
Views expressed in the submitted article represent the views of the authors and not an official position of an organization or donor